
TuHURA Biosciences Inc HURA.OQ HURA.O is expected to report resultson May 12 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for TuHURA Biosciences Inc is for a loss of 10 cents per share.
The one available analyst rating on the shares is "buy".
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
Wall Street's median 12-month price target for TuHURA Biosciences Inc is $15.00, above its last closing price of $3.93.
This summary was machine generated May 9 at 21:00 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)